Illumina expands world’s most comprehensive next-generation sequencing portfolio
New systems extend access to production-scale sequencing.
Lockheed Martin & Illumina collaborate on solutions to improve public health and wellbeing
Lockheed Martin and Illumina, Inc. have announced a new strategic alliance to collaborate on scalable and affordable genomics solutions to provide personalised health care for national populations.
£15m initiative puts Scotland at forefront of gene-led healthcare
A major investment in gene sequencing technology will secure Scotland’s place as a world leader in a genomics revolution that is set to transform healthcare.
Illumina announces AOCC to receive Agricultural Greater Good Initiative
Project designed to improve food security in Africa
Illumina and Sequenom pool noninvasive prenatal testing IP & end outstanding patent disputes
Illumina, Inc. (NASDAQ: ILMN) and Sequenom, Inc. (NASDAQ: SQNM) today announced they have agreed to settle all pending infringement claims and other disputes between Sequenom and Verinata Health, Inc. The parties will pool their owned and in-licensed intellectual property directed to noninvasive prenatal testing (NIPT), including patents that will remain the subject of ongoing interference…
USAID, Broad Institute and Illumina partner to combat Ebola epidemic in West Africa
To help combat the Ebola epidemic in West Africa, the US Agency for International Development (USAID), the Broad Institute of MIT and Harvard, and Illumina, Inc., today announced they have entered into a public-private partnership to aid those on the ground who are fighting the spread of the virus.
bioMérieux/Illumina to co-develop next-gen sequencing for monitoring of bacterial infections
bioMérieux, a world leader in the field of in vitro diagnostics, and Illumina (Nasdaq:ILMN), a world leader in genomics, announced they have signed an exclusive agreement to launch a next-generation sequencing (NGS) epidemiology solution for service labs. The two companies will jointly develop applications for microbiology sequencing technologies within a four-year renewable period.
Illumina Accelerator announces investment in inaugural startup class
Initial companies focused on breakthrough applications in therapeutics, agriculture and molecular pathology
AB SCIEX & Illumina to create world’s first multi-omics cloud-computing environment
The integration of SWATH™ apps with BaseSpace® brings next-generation proteomics and next-generation sequencing together for the first time.
Actionable Genome Consortium forms with leaders from world-renowned cancer institutions
World-renowned cancer centers and Illumina, Inc. today announced the formation of the Actionable Genome Consortium (AGC), an effort to recommend openly published standards for the widespread use of next-generation sequencing to guide decision-making in clinical oncology.
Illumina announces strategic partnerships with AstraZeneca, Janssen and Sanofi
Illumina Inc. (NASDAQ:ILMN) today announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing (NGS)-based oncology test system.
UK to become world #1 in DNA testing with plan to revolutionise fight against cancer
The UK is set to become the world leader in ground-breaking genetic research into cancer and rare diseases, which will transform how diseases are diagnosed and treated, thanks to a package of investment worth more than £300million.
Sidra to help Qatar grow as a hub for genetic medicine
Illumina’s HiSeq X Ten sequencing technology is to be implemented for population studies.
Illumina & Berry Genomics co-develop integrated next-gen system for review & approval by CRA
Berry Genomics Co. Ltd. announced today it has chosen Illumina Inc’s. (NASDAQ: ILMN) next-generation sequencing (NGS) technology as the platform on which Berry will secure Chinese Food and Drug Administration (CFDA) regulatory approval for clinical applications, thereby expanding access to NGS-based tests in China.
llumina acquires Myraqa, a leading IVD and companion diagnostic consulting firm
Illumina, Inc. (NASDAQ:ILMN) today announced that it has acquired Myraqa, a regulatory and quality consulting firm specializing in IVDs, particularly companion diagnostics.
Illumina names Tina S. Nova as Senior Vice President and General Manager of Oncology
Illumina Inc. (NASDAQ:ILMN) today announced that Tina S. Nova, Ph.D. has been named Senior Vice President and General Manager of Illumina’s oncology business.
Biomnis, Genoma and Center for Human Genetics Martinsried enter agreements with Illumina
Illumina, Inc. (NASDAQ:ILMN) today announced that it has entered into separate agreements with Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics Martinsried, under which they will use the HiSeq 2500 and consumables from Illumina to develop and perform non-invasive prenatal testing (NIPT).
Illumina acquires BlueGnome
SAN DIEGO--(BUSINESS WIRE)--Sep. 19, 2012-- Illumina, Inc. (NASDAQ:ILMN) today announced that it has acquired Cambridge, UK-based BlueGnome Ltd. for an undisclosed sum. BlueGnome, now a wholly owned subsidiary of Illumina, is a leading provider of solutions for the screening of genetic abnormalities associated with developmental delay, cancer, and infertility.
Illumina launches MyGenome® app for iPad®
SAN DIEGO--(BUSINESS WIRE) Illumina, Inc. today announced the availability of its MyGenome application for the iPad, available for download on the App Store(SM) for 69 pence (99 cents). Illumina’s MyGenome app empowers users to explore a real human genome and view reports about important genetic variations through a simple, intuitive, and educational interface for genetic data exploration and…